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Abstract
Background: The endoglycosidase EndoS and the cysteine proteinase SpeB from the human
pathogen Streptococcus pyogenes are functionally related in that they both hydrolyze IgG leading to
impairment of opsonizing antibodies and thus enhance bacterial survival in human blood. In this
study, we further investigated the relationship between EndoS and SpeB by examining their in vitro
temporal production and stability and activity of EndoS. Furthermore, theoretical structure
modeling of EndoS combined with site-directed mutagenesis and chemical blocking of amino acids
was used to identify amino acids required for the IgG glycan-hydrolyzing activity of EndoS.
Results: We could show that during growth in vitro S. pyogenes secretes the IgG glycan-hydrolyzing
endoglycosidase EndoS prior to the cysteine proteinase SpeB. Upon maturation SpeB hydrolyzes
EndoS that then loses its IgG glycan-hydrolyzing activity. Sequence analysis and structural homology
modeling of EndoS provided a basis for further analysis of the prerequisites for IgG glycan-
hydrolysis. Site-directed mutagenesis and chemical modification of amino acids revealed that
glutamic acid 235 is an essential catalytic residue, and that tryptophan residues, but not the
abundant lysine or the single cysteine residues, are important for EndoS activity.
Conclusion: We present novel information about the amino acid requirements for IgG glycan-
hydrolyzing activity of the immunomodulating enzyme EndoS. Furthermore, we show that the
cysteine proteinase SpeB processes/degrades EndoS and thus emphasize the importance of the
SpeB as a degrading/processing enzyme of proteins from the bacterium itself.
Background
Extracellular enzymes from Streptococcus pyogenes have
been extensively studied and shown to be of importance
for the pathogenesis of this human pathogen (for a review
see [1]). The secreted S. pyogenes enzyme EndoS
(AAK00850) has a specific endoglycosidase activity on
native human IgG by hydrolyzing the conserved asparag-
ine-linked glycans found on each heavy chain of IgG [2].
EndoS-activity affects the functionality of opsonizing IgG
by decreased binding to Fc-receptors and impaired classi-
cal complement activation, and EndoS treatment of
human opsonizing IgG antibodies directed towards the
cell-wall anchored M protein significantly enhances bacte-
rial survival in human blood [3]. The ndoS gene encoding
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EndoS is present in all tested isolates, and is highly con-
served. Both healthy and infected humans have circulat-
ing antibodies against EndoS, suggesting in vivo
expression [4]. In addition, EndoS is up regulated when
interacting with white blood cells [5]. The activity of
EndoS on IgG may be beneficial for S. pyogenes expressing
this enzyme with modulation and/or evasion of an IgG-
mediated response against the bacteria. In contrast to this,
the purified form of EndoS has substantial potential as a
therapeutical agent against antibody-mediated autoim-
mune diseases and other conditions where IgG is involved
in pathological processes. It has recently been shown that
pre-treatment of arthritogenic IgG antibodies with EndoS
abrogates development of arthritis in a mouse model of
collagen-induced arthritis [6].
One of the most studied streptococcal enzymes is the
cysteine proteinase, SpeB. Several in vitro and in vivo stud-
ies, as well as clinical studies have suggested a role for
SpeB as an important virulence factor [7-9]. SpeB has the
ability to degrade the human extracellular matrix protein
fibronectin and vitronectin, release inflammatory media-
tors such as interleukin 1β and bradykinin from their pre-
cursors, cleave or degrade immunoglobulins and
complement factors, and also bind to the human cell sur-
face receptors integrins [10-17]. In addition, SpeB releases
active fragments from cell wall-anchored proteins from
the bacterium itself, cleaves the secreted pore-forming
streptolysin O that retains its cytolytic activity after
processing, and degrades superantigens [18-20].
EndoS and SpeB from S. pyogenes are functionally related
in that they both hydrolyze IgG leading to impairment of
opsonizing antibodies and thus enhance bacterial survival
in human blood [3].
In this study, we further investigated the relationship
between EndoS and SpeB by examining their in vitro tem-
poral production and reveal a novel activity of SpeB;
processing and eventually complete degradation of EndoS
with loss of its IgG hydrolyzing activity. Furthermore, the-
oretical structure modeling of EndoS combined with site-
directed mutagenesis and chemical blocking of amino
acids identified amino acids required for the IgG glycan-
hydrolyzing activity of EndoS.
Results and Discussion
Temporal production of EndoS and SpeB
S. pyogenes strain AP1 was cultured in a medium for opti-
mal expression of EndoS and SpeB [2,21], and culture
supernatant samples were withdrawn at indicated time
points (Fig. 1A). Secretion of SpeB and EndoS was ana-
lyzed using Western blots with polyclonal rabbit antise-
rum raised against the zymogen form of SpeB and full-
length EndoS. Expression of intact EndoS (108 kDa) was
observed after approximately 9 hours in late exponential
growth phase (Fig. 1A and 1B). However, when samples
were collected at 12 hours of incubation an additional
band with an apparent mass of 62 kDa reacted with the
EndoS antibodies (Fig. 1A and 1B). Furthermore, the total
amount of the 62 kDa band decreased between 15 and 24
hours of culturing suggesting further degradation of this
fragment of EndoS. Interestingly, the appearance of this
62 kDa EndoS fragment coincides with the maturation
and processing of SpeB from its 40 kDa zymogen form
into its proteolytically active 28 kDa form (Fig. 1C). This
observation suggested that SpeB is involved in the
processing/degradation of EndoS, and we hypothesized
Secretion of EndoS and SpeB during growth of S. pyogenes  strain AP1 Figure 1
Secretion of EndoS and SpeB during growth of S. 
pyogenes strain AP1. Panel A, growth of wild type AP1 and 
measurements of optical density at 620 nm over time. Sam-
ples were withdrawn for analysis at indicated time points. 
Panel B, detection of EndoS in samples from indicated time 
points using antiserum against full-length EndoS. Panel C, 
detection of SpeB in the culture supernatants using antiserum 
against the 40 kDa zymogen form of SpeB.BMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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that this could be of importance in regulating EndoS
activity.
SpeB hydrolyzes EndoS during growth and in purified form
In order to confirm that SpeB hydrolyzes EndoS, we cul-
tured the wild type strain AP1 for 20 hours in CM with or
without the reducing agent DTT (SpeB activity requires
reducing conditions [22]) and analyzed the status of
EndoS and SpeB using Western blots. Under reducing
conditions the AP1 strain nearly completely degraded
EndoS protein, while under the slightly reducing condi-
tion in CM alone EndoS was only partly hydrolyzed (Fig.
2A, EndoS, lanes A and B), which suggests that SpeB is
responsible for the hydrolysis of EndoS. Analysis using
SpeB antibodies revealed that under non-reducing condi-
tions the AP1 strains produces mainly the 28 kDa active
form of SpeB, but some 40 kDa could be detected, while
under reducing conditions only the active form of SpeB
could be detected (Fig 2B, SpeB, lanes A and B). The 62
kDa band reacting with the EndoS antibodies in lane A
figure 2A was sequenced by Edman degradation [23]
revealing the sequence KDKSYDLI corresponding to
amino acids 446–453 of the EndoS sequence
(AAK00850). Thus, one SpeB cleavage site in EndoS is
between Leu-445 and Lys-446, but smaller degradations
products reacting with the antibodies could also be seen.
To confirm SpeB activity on EndoS, we cultured the iso-
genic SpeB mutant AL1 [2,24] in CM and analyzed the
supernatant as above. This showed that AL1 is unable to
hydrolyze EndoS even in the presence of DTT (Fig. 2A,
EndoS, lanes C and D). A confirmation that AL1 does not
produce any active SpeB is seen in (Fig. 2B, SpeB, lanes C
and D). As a control experiment, strain MC14 mutated in
the ndoS gene was analyzed under the same conditions.
This revealed that MC14 does not produce any EndoS
(Fig. 2A, EndoS lanes E and F), while it still produces SpeB
as wild type AP1 (Fig. 2B, SpeB, lanes E and F). Taken
together, SpeB cleaves EndoS into a main 62 kDa frag-
ment and several smaller fragments during growth, but it
remained unclear whether the remainder of EndoS was
completely degraded or simply not recognized by the
EndoS-antibodies.
To further investigate the hydrolysis of EndoS, recom-
binantly expressed EndoS (rEndoS) was incubated with
serial dilutions of SpeB. This revealed that SpeB processes
rEndoS into two major fragments of approximately 62
and 46 kDa (Fig. 2B, lane E). Visual inspection and whole
lane densitometry analysis (Fig 2C) showed that the total
amount of rEndoS also diminished, indicating that
besides processing into two fairly stable fragments, SpeB
unspecifically degrades EndoS into low molecular weight
fragments. In addition, EndoS was incubated at an
enzyme: substrate ratio of 1:3 with thermolysin for one
hour. Despite 296 predicted thermolysin sites in the
EndoS is hydrolyzed by SpeB Figure 2
EndoS is hydrolyzed by SpeB. Panel A, analysis of SpeB-
hydrolysis of EndoS during growth of the wild type AP1 
(lanes A and B), the SpeB mutant AL1 (lane C and D), and 
the EndoS mutant MC14 (lanes E and F) with antiserum 
against EndoS and SpeB. Presence or absence of DTT during 
growth is indicated under the lower panel. Arrows to the 
right indicate the positions of full-length EndoS (FL), the 
zymogen (Z) and proteinase (P) forms of SpeB. Panel B, rEn-
doS incubated with increasing amounts of SpeB (lanes A-E) 
or thermolysin (lane F) as indicated and analyzed by SDS-
PAGE. Arrows to the right indicate the positions of the 46- 
and 62-kDa forms of EndoS, SpeB, and thermolysin. Panel C, 
densitometric analysis of whole lanes A-E (excluding SpeB) in 
panel B. Values are presented as area under the curve in 
pixels.BMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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mature 108 kDa form of EndoS, two major fragments of
approximately 62 and 46 kDa, similarly to what could be
seen with SpeB, resisted proteolysis (Fig. 2B, lane F).
Analysis of primary structure and homology modeling of 
EndoS
EndoS contains a 37 amino acids N-terminal signal
sequence that has been verified by amino-terminal
sequencing [2], an amino-terminal part comprising
amino acids 37–446 which harbors a family 18 glycosyl
hydrolase active site motif at position 227–235 [25] (Fig.
3A). The remaining part (amino acids 446–995) of EndoS
carboxy-terminally to the SpeB cleavage site (Fig. 3A. 446–
995) is similar to leucine-rich repeat proteins (LRR's)
from the oral pathogen Porphyromonas gingivalis [26], the
tetanus-causing Clostridium tetani [27], and from the intra-
Possible domain organization and sequence alignments of EndoS Figure 3
Possible domain organization and sequence alignments of EndoS. Panel A, schematic representation of the 995 
amino acids EndoS. Ss indicates signal peptide, the chitinase family 18 active site motif in the amino-terminal domain is indi-
cated, the SpeB cleavage site is indicated with an arrow, and the putative leucine-rich repeat region (LRR) is shown. Panel B, 
ClustalW alignment of EndoS and leucine-rich proteins from P. gingivalis (NP_905954), C. tetani (NP_781184), and L. monocy-
togenes (NP_463795). Amino acid number one corresponds to amino acid 446 in the whole protein. Panel C, RADAR repeat 
analysis showing three 37 amino acids leucine rich repeats and two additional repeats. Numbering is based on the 995 amino 
acids sequence of full-length EndoS.BMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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cellular pathogen Listeria monocytogenes (Internalin E,
InlE) [28] (Fig. 3B). No functions have been ascribed to
the LRR's most similar to EndoS, but LRR's belonging the
internalin family of proteins from Listeria spp. are essential
for cellular attachment and internalization through bind-
ing of E-cadherin [29,30]. EndoS contains three highly
similar leucine-rich repeats of approximately 37 amino
acids between amino acids 459 and 589, and two addi-
tional repeats between 591 and 683 with lower leucine
content and with a somewhat lower similarity as detected
by the RADAR algorithm [31](Fig. 3C).
Despite a wide variety of folds, the overall topology of gly-
cosyl hydrolases can be divided into three main groups
where the active site is within a pocket, a cleft or a tunnel.
The varying degree of accessibility to the active site has
been suggested to determine the carbohydrate substrate
specificity [32]. Since the only substrate for EndoS known
to date is the complex bi-antennary glycan on native IgG,
we attempted to predict the structure of EndoS using
homology modeling. Amino acids 37–446 of EndoS was
aligned with EndoF3 from Elizabethkingia meningoseptica
(formerly Flavobacterium meningosepticum) [33] and sub-
jected to automated protein homology modeling using
EndoF3  (PDB 1EOK) as the template. The generated
model of amino acids 37–446 covers the active site and
displays a typical (α/β)8-barrel with eight repeated β-
strand/loop/α-helix units with the parallel β-strands
forming an eight-stranded β-barrel (Fig. 4A). The putative
catalytic Glu-235 residue in the FGH18 active site is
located at the orifice of the β-barrel. When superimposing
the EndoS model on the EndoF3 structure, two additional
antiparallel β-strands protrudes at the top of the barrel
close to the catalytic Glu residue, and there are two
extended loops with antiparallel β-strands on opposite
sides of the molecule. Both EndoS and EndoF3 hydrolyse
biantennary complex carbohydrates [2,33]. The modeled
β-barrel in EndoS potentially only accommodates certain
glycans and could partly explain EndoS' specificity for the
N-linked carbohydrate on human IgG, even though its
Homology modeling of EndoS Figure 4
Homology modeling of EndoS. Panel A, model of amino 
acids 37–446 of EndoSusing EndoF3 as the template. Glu-235 
in the active is shown in red. Panel B, EndoS model (yellow) 
superimposed in the structure of EndoF3 (blue). Panel C, 
model of amino acids 446–557 of EndoS using the LRR-
region from InlB as the template. Panel A and C, β-strands 
are shown in yellow, α-helices in purple, and loops in tur-
quoise.
Glutamic acid 235 and tryptophan residues are important for  EndoS activity Figure 5
Glutamic acid 235 and tryptophan residues are 
important for EndoS activity. Panel A, homology model 
of the amino-terminal part of EndoS with glutamic acid 235 
(red) and the tryptophan residues (blue) are highlighted. 
Panel B, dilutions of rEndoS or rEndoS(E235Q) incubated 
with 1 μg human IgG for 1 hour at 37°C. IgG-glycan hydroly-
sis by EndoS was analyzed by SDS-PAGE and LCA-blot. Panel 
C, human IgG incubated with buffer, rEndoS modified with 
NEM, NBS, IAA, or unmodified (Buffer). The proteins were 
separated by SDS-PAGE, stained or analyzed for LCA reac-
tivity in blot.BMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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activity has been suggested to depend on additional pro-
tein-protein interactions [34]. Hypothetically, the addi-
tional extended loops in the EndoS could contribute to
the specificity by interactions with the protein backbone
of the IgG heavy chain. Homology models should be
interpreted with great caution, but the EndoS model could
serve as a starting point for rational mutagenesis, interac-
tion studies with IgG, and attempts to crystallize defined
parts of the molecule.
Since EndoS contains LRR's with similarities to other bac-
terial LRR proteins we attempted to generate a model of
this region to investigate if EndoS has the potential of
adopting a similar structure known to be important for
protein-protein interaction and virulence in Listeria spp.
Using the same approach as for the amino-terminal part
we were able to construct a model of amino acids 446–
577 of EndoS using the LRR region of Internalin B (InlB,
PDB 1M9S) from Listeria monocytogenes as a template [35].
This model revealed a bowed tube structure with five par-
allel β-strands forming a β-sheet that constitute the con-
cave face of the structure in a similar manner as can be
seen in InlB (Fig. 4C). In the EndoS-LRR model there is
only one complete β-loop-helix-loop motif that can be
seen in several LRR proteins including InlB. Furthermore,
it is unclear from this model if the carboxy-terminal part
of EndoS has the kind of cap structure that can be seen in
InlB. Nevertheless, it is intriguing that a secreted S. pyo-
genes protein has structural similarity with LRR's of inter-
nalins that are crucial for cellular invasion and virulence.
Furthermore, since the concave face of other LRR's includ-
ing InlB has been suggested to be a major site for protein
interactions, the model of the LRR region in EndoS could
be used as a starting point for finding potential cellular
and protein targets in the human host.
Site-directed mutagenesis and chemical modification of 
tryptophans inactivates EndoS
Sequence analysis suggested that Glu-235 is part of the
glycosyl hydrolase motif and possibly the catalytically
active amino acid. Furthermore, the positioning of Glu-
235 at the orifice of the -barrel as suggested by homology
modeling identified this amino acid as prime catalytic res-
idue candidate (Fig. 5A). Therefore we mutated Glu-235
in rEndoS to glutamine by site-directed mutagenesis of
the  ndoS  gene and recombinantly expressed
EndoS(E235Q). This protein was tested for activity against
purified human IgG by SDS-PAGE and lectin blot analy-
sis. This revealed that EndoS, but not EndoS(E235Q)
could shift the apparent mass of the IgG heavy chain
approx. 3 kDa (Fig 5B, Stain) indicating that
EndoS(E235Q) has lost its activity on IgG. Furthermore,
IgG heavy chains incubated with EndoS but not
EndoS(E235Q) loose the reactivity against the mannose-
specific biotinylated lectin Lens culinaris agglutinin (LCA)
(Fig 5B, LCA-blot). We have previously shown that lack of
lectin signal from IgG corresponds well to complete
hydrolysis of the chitobiose core of the IgG-glycan as ana-
lyzed by mass spectroscopy of hydrolyzed IgG [36]. This
experiment confirmed that Glu-235 is essential for the
IgG-glycan hydrolyzing activity of EndoS.
Another approach to investigate which amino acids that
are important for enzymatic activity involves chemical
modification of certain types of amino acids. It has previ-
ously been shown that chemical blocking of tryptophans
in a β-N-acetylglucosaminidase from the mollusk Batillus
cornutus (formerly Turbo cornutus) inhibits chitinase activ-
ity [37]. Furthermore, tryptophans situated on extended
loops outside the catalytic site are essential for substrate
binding and enzymatic activity in a chitinase from Strepto-
myces griseus [38,39]. This was intriguing, since 8 tryp-
tophans are present in the amino-terminal part of EndoS
of which one is located inside the predicted -barrel with
Glu-235 at the orifice, and three (two and one) in the pre-
dicted extended loops that distinguish EndoS from the
template EndoF3 (Fig 5A). Furthermore, there are four
more tryptophan residues in the carboxy-terminal part
located carboxy-terminally to the LRR. Therefore we inves-
SpeB-hydrolyzed rEndoS loses activity on human IgG Figure 6
SpeB-hydrolyzed rEndoS loses activity on human 
IgG. Panel A, rEndoS was incubated with SpeB as described 
in material and methods at indicated time points and 10 μl of 
samples were applied on polyacrylamide gel and stained with 
Coomassie Blue. Panel B, 2 μl sample withdrawn from the 
same incubations, was incubated with 2 g IgG for 2 hours and 
IgG hydrolysis was analyzed by SDS-PAGE and LCA-blot.BMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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tigated if N-bromosuccinimide (NBS) could affect the
enzymatic activity of EndoS. NBS can react with the indole
group of tryptophan and with SH groups of cysteines and
are commonly used for characterization amino acid resi-
dues involved in enzymatic activity [40]. After modifica-
tion of EndoS with NBS, no IgG glycan hydrolysis could
be seen as analyzed by SDS-PAGE and LCA lectin blot
analysis (Fig. 5C, Stain and LCA-blot). Treatment of
EndoS with iodoacetamide (IAA) or N-ethylmaleimide
(NEM), reagents used for blockage of cysteines (Fig. 5C,
Stain and LCA-blot, NEM and IAA), or modification of
lysines using formaldehyde, did not affect the hydrolysis
of IgG by EndoS (data not shown). These results suggest
that lysine (constitutes 10% of the amino acids) and
cysteine residues (one in the mature protein) in EndoS are
not essential for the enzymatic activity, while tryptophans
in the predicted β-barrel, in the extended loops, and/or in
the carboxy-terminal part are required for the IgG glycan-
hydrolyzing activity of EndoS.
SpeB ultimately inactivates EndoS
To investigate whether SpeB-hydrolyzed EndoS has activ-
ity on the glycan on IgG, rEndoS was treated for increasing
amount of time with SpeB prior to incubation with
human IgG. This revealed that SpeB hydrolyzes EndoS in
a time-dependent manner and that after 2 hours of incu-
bation virtually no full-length EndoS is present. The
smaller protein fragment can still be detected after 4 hours
and the larger fragment can be detected after 3 h (Fig. 6A).
This corresponds well to the observations of the presence
and state of the two enzymes during growth of S. pyogenes;
when active SpeB starts to appear after 12–13 hours of
growth the first signs of EndoS-hydrolysis can be seen,
and 2–3 hours later no full-length EndoS can be detected
(Fig. 1 and data not shown). Furthermore, the IgG glycan-
hydrolyzing activities of the same samples were analyzed
by SDS-PAGE and LCA lectin blot. This revealed that after
3 hours of incubation no IgG glycan hydrolyzing activity
could be detected (Fig. 6B, Stain and LCA-blot). This indi-
cates that full-length EndoS is required for activity on IgG
and that SpeB eventually inactivates the IgG glycan-hydro-
lyzing activity of EndoS.
In this study we show that EndoS and SpeB are coordi-
nately expressed during growth in vitro, and that when
SpeB maturates into its active form it starts to degrade
EndoS, but two major fragments of 62 and 46 kDa seems
somewhat more resistant to proteolysis. Fragments of
similar sizes are also generated by the protease thermo-
lysin suggesting that there are domains in EndoS that are
partly protected against proteolysis, of which one most
likely is the 62 kDa carboxy-terminal fragment identified
by amino-terminal sequencing. SpeB-processing and/or
degradation of proteins from the bacterium itself seem to
be important mechanisms for inactivation or release of
biologically active fragments or domains. SpeB processes
the pore-forming streptolysin O [19], releases functional
fragments from the cell-wall anchored C5a-peptidase and
IgG-binding M proteins [18], and degrades the streptococ-
cal superantigen SmeZ [20]. Such a process might be of
importance in controlling the enzymatic activity of EndoS
or to release fragments with biological activity, but at this
point we could only substantiate the former. Interestingly,
a recent study has shown in a mouse model of subcutane-
ous infection that S. pyogenes undergoes a stable phase
shift to low SpeB production leading to production of
intact forms of several putative and known virulence fac-
tors including EndoS [41]. This further emphasizes the
role for SpeB in controlling the activity of other secreted
and cell wall-anchored proteins during the infection
process.
Attempts to recombinantly express the amino- and car-
boxy-terminal parts of EndoS separately for functional
studies have this far proven unsuccessful. The amino-ter-
minal part could be expressed in E. coli, but the protein is
degraded despite the use of protease-deficient host strains,
while the gene fragment encoding the carboxy-terminal
part could not be established in E. coli for unknown rea-
sons (data not shown). Furthermore, we have not been
able to separate the SpeB generated fragments of EndoS
using gel filtration, ion-exchange chromatography, or
affinity chromatography with immobilized EndoS anti-
bodies (data not shown).
Homology modeling, site-directed mutagenesis, and
chemical modification experiments of EndoS suggest that
the amino-terminal part contains several key elements
necessary for enzymatic activity on human IgG. The func-
tion of the carboxy-terminal part remains unknown, but
the observation that only full-length EndoS has activity
on IgG indicates that also this part of the protein is
important for the interaction with IgG, either as necessary
structural element or by direct interactions with IgG. The
primary and possible structural similarities between
EndoS and LRR's from other pathogenic bacteria suggest
that it might have similar adhesive or invasive functions
either as a liberated domain or in the intact enzyme.
Interestingly, another recently identified extracellular S.
pyogenes  LRR protein; Slr (streptococcal leucine-rich
repeat protein) is involved in virulence and phagocytosis
resistance [42]. Our findings may in part explain why
EndoS in contrast to many related endoglycosidases, that
require or are enhanced by denaturation of the glycopro-
tein, only interacts with native IgG [34]. A protein-pro-
tein interaction between the enzyme and IgG involving
tryptophan residues in EndoS could be part of this
unique feature.BMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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It is currently not known how the IgG-hydrolyzing activi-
ties of SpeB and EndoS contributes to the pathogenesis of
S. pyogenes infections, even though the attenuation seen in
SpeB mutants might include loss of activity agianst IgG.
There are fundamental differences between the two
enzymes despite their shared substrate; SpeB is a broad
spectrum protease with activities against a whole array of
host proteins while EndoS is very specific for IgG. This
might give a hint about their respeictive contribution to
IgG hydrolysis. SpeB most likely contributes to IgG
hydrolysis during infections but there will be many com-
peting substrates that will lower the effeciency against IgG.
It should also be mentioned, that S. pyogenes possesses
another cysteine proteinase, IdeS, that in contrast to SpeB
only hydrolyzes IgG [43]. EndoS on the other hand could
at low concentrations efficeintly incapacitate IgG during
certain stages of the infection. Our current model hypoth-
esizes that EndoS most likely plays a minor role in ani-
mals without aquired immunity towards S. pyogenes and
only comes into play when there are circulating antibod-
ies towards the bacteria. We are currently setting up ani-
mal models to test this hypothesis. Animals will be
immunized with surface structures from S. pyogenes prior
to challenge with wild type bacteria and an isogenic
mutant in the ndoS gene. This might help us to further elu-
cidate the role for EndoS during infections.
Conclusion
The cysteine proteinase SpeB processes, inactivates, and
ultimately degrades the IgG glycan-hydrolyzing enzyme
EndoS. Glutamic acid 235 in EndoS is required for glycan-
hydrolyzing activity and tryptophans in EndoS are
involved in the enzymatic activity on human IgG. This is
important information for future studies of the function
and presence of EndoS in various systems. Since SpeB and
EndoS are expressed during the same conditions (in vitro
and possibly during some conditions in vivo), researchers
setting out to study EndoS are bound to experience degra-
dation/inactivation of EndoS if not the temporal produc-
tion and activity of both enzymes are taken into account.
Methods
Bacteria and growth conditions
The S. pyogenes strains that were used in this study are AP1
of serotype M1 from the WHO Collaborating Center for
Reference and Research on Streptococci, Prague, Czech
Republic; AL1, an isogenic mutant of AP1 lacking produc-
tion of active SpeB generated as previously described
[2,24]; MC14, an isogenic mutant of AP1 lacking produc-
tion of EndoS generated as previously described [2]. For
maximal SpeB and EndoS expression, C-medium (CM)
was used consisting of 0.5% (w/v) Proteose Peptone No.
2 (Difco, Detroit, MI) and 1.5% (w/v) yeast extract
(Oxoid, Basingstoke, England) dissolved in CM buffer (10
mM K2PO4, 0.4 mM MgSO4, and 17 mM NaCl pH 7.5)
[21]. When appropriate, a final concentration of 5 mM
dithiothreitol (DTT) was added to the growth medium to
activate SpeB. Strains AL1 and MC14 were cultured in the
presence of 200 μg/ml of kanamycin for selective pressure.
Protein electrophoresis and Western blots
Culture supernatants were precipitated using trichloroace-
tic acid at a final concentration of 5% and separated by
10% SDS-PAGE [44] followed by transfer to PVDF mem-
branes (Immobilon-P, Millipore, Bedford, MA) by elec-
troblotting. Secretion of SpeB and EndoS was analyzed
using Western blots with polyclonal rabbit antiserum
raised against the zymogen form of SpeB and full-length
EndoS as previously described [2,45]. Densitometric anal-
ysis of stained SDS-PAGE gels was performed using the
public domain software ImageJ 1.39f developed by
Wayne Rasband at the National Institutes of Health http:/
/rsb.info.nih.gov/ij/.
Proteins and enzyme activity assays
Full-length EndoS with (GST-EndoS) or without (rEndoS)
glutathione-S-transferase (GST) as a fusion partner was
recombinantly expressed and purified from Escherichia coli
harboring the plasmid pGEXndoS as previously described
[34]. The native zymogen form of SpeB was purified from
S. pyogenes strain AP1 using ion-exchange chromatogra-
phy as previously described [18]. The immunoglobulins
used in all experiments were affinity purified pooled
human polyclonal IgG (Sigma, St. Louis, MO). For testing
of SpeB activity on EndoS, 30 μg of rEndoS was incubated
for 2 hours at 37°C with 1, 0.2, 0.04, or 0.008 μg of puri-
fied SpeB in 20 μl PBS with a 10 mM final concentration
of DTT followed by 10% SDS-PAGE analysis. For testing
of thermolysin degradation 10 μg of rEndoS was incu-
bated with 1 μg of thermolysin (Sigma) [46] for 1 hour at
37°C in 10 mM Tris-HCl (pH 7.4) and analyzed on SDS-
PAGE as above. Alternatively, 30 μg of rEndoS was incu-
bated at 37°C with a fixed amount of SpeB (6 μg) in a
final volume of 120 μl under the same conditions as
above and samples were withdrawn at 1 or 30 min, and 1,
2, 3 or 4 hours. Reactions were terminated by a final con-
centration of 100 μM E-64 (L-trans-epoxysuccinylleucyla-
mido(4-guanidino)butane), a specific cysteine proteinase
inhibitor [47] followed by 10%SDS-PAGE analysis.
EndoS activity on IgG was measured by withdrawing 2 μl
of samples from the above mixture and incubated it with
2 μg of purified human IgG for 2 hours at 37°C followed
by separation by 10% SDS-PAGE, or electroblotted onto
PVDF membranes (Millipore). Glycosylated IgG was
detected using 5 μg/ml of biotinylated Lens culinaris agglu-
tinin lectin (LCA) and 1 μg/ml of Streptavidin-Horserad-
ish peroxidase (Vector Laboratories, Burlingame, CA) and
SuperSignal West Pico peroxidase substrate (Pierce, Rock-
ford, IL). Membranes were analyzed using a ChemidocBMC Microbiology 2008, 8:3 http://www.biomedcentral.com/1471-2180/8/3
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XRS imaging system and Quantity One image analysis
software (Bio-Rad, Hercules, CA).
Homology modeling
Amino acids 37–446 of EndoS was aligned with EndoF3
from Elizabethkingia meningoseptica (formerly Flavobacte-
rium meningosepticum) [33] using the T-Coffee method
[48] and submitted to the SWISS-MODEL automated pro-
tein homology server [49,50] using EndoF3 (PDB 1EOK)
as the template. The generated model was visualized using
the VMD 1.8.5 software [51] and high resolution images
were generated using POV-Ray 3 [52] running on a Mac
OS X workstation.
Chemical modification of EndoS
Chemical modification of tryptophan residues was per-
formed according to [37]. Briefly, 20 μg of rEndoS was
incubated with 0.5 mM N-bromosuccinimide (NBS)
(Sigma) in 20 μl of 0.1 M citric acid-Na2HPO4, pH 4.5 for
30 minutes at room temperature. Chemical modification
of cysteine residues as performed by incubating 20 μg of
rEndoS with 10 mM N-ethylmaleimide (NEM) (Sigma) in
20 μl of 0.1 M citric acid-Na2HPO4, pH 6 for 30 minutes
at room temperature or with 20 mM iodoacetamide (IAA)
(Sigma) in 20 mM Tris-HCl, pH 8.5 for 30 minutes at
room temperature. For determination of enzymatic activ-
ity, 0.5 μg rEndoS from the above reaction mixtures was
incubated with 10 μg human IgG in 20 mM Tris-HCl, pH
7.4 for 2 hours at 37°C. Samples were separated by 10%
SDS-PAGE and stained with Coomassie or electroblotted
onto PVDF for analysis with LCA lectin blot as above.
Site-directed mutagenesis of EndoS
Mutation of glutamic acid 235 (Glu-235) into glutamine
(E235Q) was performed using QuickChange II Site-
Directed Mutagenesis Kit according to manufacturer's
instructions (Stratagene, La Jolla, CA). The mutagenic oli-
gonucleotide primers (mutation underlined) used was 5'-
CCT TGA TGG CTT AGA TGT GGA TGT TCA ACA TGA
TAG TAT TCC-3' for E235Q in combination with the anti-
sense of the above sequences and the plasmid pGEXndoS
generating plasmid pGEXndoS(E235Q). Mutation was
verified by sequencing. Recombinant EndoS(E235Q) was
expressed and purified as described above for EndoS.
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